GCC markets led higher in April tracking global optimism: Kamco Invest
MSCI GCC Index gained 4.5% pushed year-to-date gains to nearly 18%
ZAWYA - 03 May 2021
Dallah Healthcare Company (4004.SE)
Also known as: DHC, Dallah Health
76.90 SAR 0.000.00%
DHC Stock Price & Performance
Recommendation
-
Div Yield
-
P/E (Last 12 Month)
51.47
Upside
-
Target Price (Mean)
-
Open
77.00 SAR
Previous Close
76.90 SAR
Turnover
1.64M SAR
EPS
1.49 SAR
Volume
21,345
Transactions
197
Market Cap
6.58B SAR
IPO Date
16-Dec-2012
Analyst Estimates
| EPS | Revenue | |
|---|---|---|
| Mean Estimate |  | |
| Smart Estimate | | |
| Predicted Surprise | | |
| Mean Chg % | | |
Starmine Models
StarMine provides a suite of proprietary alpha-generating analytics and models spanning sectors, regions, and markets.
| Bullish | |
|---|---|
| Value Momentum | |
| Intrinsic Valuation | |
| Relative Valuation | |
| Credit Risk - Smart Ratios | |
| Credit Risk- Text Mining | |
| Bearish | |
|---|---|
| Price Momentum | |
About Dallah Healthcare Company
Business Summary
Ownership and operation of general hospitals. Through its main subsidiaries, manufacture of branded drugs; distribution of pharmaceuticals; offers hospital and medical center maintenance services.
Country of Incorporation
Ownership Type
Established In
1994
Primary Sector
Stock Listing
| ID | Stock Type | Currency | Exchange | Symbol |
|---|---|---|---|---|
| 4004.SSE | Ordinary | SAR | Saudi SE | 4004 |
Contact details
Primary address
Building: Al Nakheel TowerStreet: King Fahad Road 1157
Floor: 2nd Floor
Area: Al Nakheel Area
P.O. Box: 87833
Country: Saudi Arabia
City: Riyadh
City Suffix: 12381
CONTACT
- Tel: +966 11-299-5555
- Tel: +966 11-225-5065
- Tel: +966 11-225-5769
- Fax: +966 11-470-2748
- Fax: +966 11-225-0602
- Fax: +966 11-455-0803
- Email: info@dallahhealth.com
- www.dallahhealth.com
Region
RiyadhOwnership
Ownership
| Investor | Holding | No. of Shares | Last Update |
|---|---|---|---|
| | | |
| | | |
Holding Concentrations
| Investor | Holding | No. of Shares | Last Update |
|---|---|---|---|
| | | |
| | | |
Financials
Revenue
Net Income
Profit Margin
Total Assets
Total Liabilities
Debt to Assets
Operating
Investing
Financing
Executives
Dr Ahmad Bin Saleh Mohammed Babaeer
Chief Executive Officer and Managing Director
Mr Khalid Mohammed Ali Al Saudi
Chief Financial Officer
Dr Salah Rashed Al Faqih
Chief of Medical Staff
Board Members
Mr Tariq Al Qusabi
Chairman
Mr Mohieddine Saleh Abdullah Kamel
Vice Chairman
Dr Mohammed Rashed Mohammed Al Fagih
Director
Company information provided by Refinitiv
Refinitiv research team update company information from primary sources (company annual reports, press releases, company websites, corporate briefings, official statements/interviews) and reliable secondary sources (stock markets, reliable third party publications).
Zawya Coverage
Top Middle East corporates that announced Q2, H1 results today
Saudi Arabia plans $15bln technology fund with private investors- report
Global sustainable bond issuance to reach a record $850bln in 2021
UAE central bank maintains base rate on deposits at 15 basis points
Economic outlook: Bahrain needs to focus on financing needs; oil to help recovery
Thursday Outlook: Chinese stocks in tentative bounce; oil prices remain near $75
Gold hits one-week high; Powell presses pause on dollar's rally
Stock Market Data
Powered By Knowledge Direct